AAOI vs MANH

AAOI's deterministic health scores are severely compromised: the Piotroski F-Score of 0/9 signals extreme financial distress, with no positive indicators in profitability, leverage, or cash flow. The Altman Z-Score is unavailable, but the company's negative ROE (-7.94%), negative profit margins (-8.39%), and persistent losses despite 33.9% revenue growth indicate deep operational inefficiency. While the stock has delivered extraordinary price appreciation (510% in 1Y), this is not supported by fundamentals, and the valuation (P/E 30.28, Price/Sales 15.97) reflects a premium driven by speculative momentum rather than intrinsic value. Insider selling of $23.77M in the last 6 months further undermines confidence, signaling potential misalignment with public investors.

MANH exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 71.66%, though it lacks an Altman Z-Score for bankruptcy risk assessment. While the company has a stellar 25-quarter track record of earnings beats, the stock is currently in a severe technical downtrend, losing over 37% of its value in the last six months. The current price of $126.11 trades at a significant premium to both the Graham Number ($20.64) and the growth-based Intrinsic Value ($79.74). Despite a bullish analyst target of $208.55, the combination of slow revenue growth (5.7%) and bearish insider sentiment warrants a neutral stance until price stabilization occurs.